Holen Sie sich die Stockscreener-App
540.03
0.62%
-3.37
Schlusskurs vom Vortag:
$543.40
Offen:
$543.18
24-Stunden-Volumen:
883.18K
Relative Volume:
0.87
Marktkapitalisierung:
$23.16B
Einnahmen:
$3.17B
Nettoeinkommen (Verlust:
$1.29B
KGV:
19.93
EPS:
27.0947
Netto-Cashflow:
$1.01B
1W Leistung:
+1.36%
1M Leistung:
+7.93%
6M Leistung:
-6.50%
1J Leistung:
+24.95%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$523.95
$555.59
52-Wochen-Spanne:
$409.07
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
540.03 | 23.16B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
19.01 | 60.73B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.72 | 47.49B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.68 | 42.57B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.29 | 31.11B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-01 | Hochstufung | BTIG Research | Neutral → Buy |
| 2026-09-24 | Eingeleitet | Goldman | Sell |
| 2026-05-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Liquidia Shares Surge 42.48% After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Just Paid $380 Million to End a Patent War That Crushed the Stock - Money Morning
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH - The Manila Times
Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. - Stock Titan
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 12 October - Investing.com Canada
The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Corporation Presents New Data Across Its Commercial and Development Portfolio At the CHEST 2026 Annual Meeting - marketscreener.com
An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring - Stock Titan
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting - Yahoo Finance
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com UK
United Therapeutics CEO Rothblatt sells $5.2m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.2m in stock - Investing.com
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com Nigeria
United Therapeutics CEO Martine Rothblatt sells $5.1m in shares - Investing.com
Form 4 United Therapeutics Corporation For: 10 October By Investing.com - Investing.com Nigeria
Is United Therapeutics Corp (UTHR) Overvalued After 3.1% Rally? - GuruFocus
After exercising 9,500 options, the CEO’s trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
McDermott team recognized by Law.com’s Litigation Daily for patent trial win for United Therapeutics - McDermott Will & Schulte
United Therapeutics chairperson & CEO Martine Rothblatt sells $5.2m in stock - Investing.com
The CEO's family trust exercises options and sells 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Family trusts sell 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
United Therapeutics Wipes Sandoz $70.6 Million Remodulin Win (1) - Bloomberg Law News
After exercising options at $117.76 per share, United Therapeutics (UTHR) CEO trust sells 9,500 shares. - Stock Titan
CEO trusts sold 9,500 United Therapeutics (UTHR) shares after exercising options at $117.76 each. - Stock Titan
After exercising 9,500 options, a CEO family trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics chairperson & CEO Rothblatt sells $1.06m - Investing.com
United Therapeutics EVP sells $4.69m in shares after option exercise - Investing.com
United Therapeutics CEO Martine Rothblatt disposes of $3.9m in stock - Investing.com
An 8,300-share sale followed an option exercise by United Therapeutics (UTHR) counsel Paul A. Mahon. - Stock Titan
Family trusts sell 1,920 United Therapeutics (UTHR) shares under CEO Rothblatt's trading plan. - Stock Titan
CEO family trusts sell 7,580 shares as United Therapeutics (UTHR) reports a 9,500-option exercise. - Stock Titan
United Therapeutics Jumps 13% After Court Backs Key Patent Claims Against Liquidia - finance.biggo.com
United Therapeutics Corp Stock (UTHR) Moved Up by 7.26% on Oct 1: What Investors Need To Know - tradingkey.com
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - Zacks Investment Research
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia - Benzinga
Why is United Therapeutics stock gaining today? - Investing.com
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? - Zacks Investment Research
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? - Yahoo! Finance Canada
United Therapeutics Corporation wins Yutrepia PH‑ILD patent ruling - Mugglehead Investment Magazine
United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent - Yahoo Finance
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 13 '26 |
Sale |
545.52 |
9,500 |
5,182,414 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 12 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 12 '26 |
Sale |
550.70 |
9,500 |
5,231,666 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 09 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 09 '26 |
Sale |
544.94 |
9,500 |
5,176,936 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 08 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 08 '26 |
Sale |
534.31 |
9,500 |
5,075,919 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 07 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 07 '26 |
Sale |
548.95 |
9,500 |
5,215,015 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 06 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
1.10%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):